Welcome - Register - Login - Help/FAQ - 0 items

Search Enter keywords, a title or a report id number below. In All Categories --------------------- Telecom & Computing Business & Finance Mfg & Construction Pharma & Healthcare Consumer & Retail Gov & Public Sector Energy & Transport Country Reports Company Reports --------------------- Transcripts Advanced      Select a currency for use throughout the site Australia Dollars Canada Dollars Euro Japan Yen Sweden Kroner Switzerland Francs UK Pounds US Dollars Search Results Your Search for 'Angiogenesis Modulators: Strategies for Drug Discovery' returned 15 results - Page 1 of 1   Sort by    Date Published ASC Date Published DESC Report Price ASC Report Price DESC Rank ASC Rank DESC   Sorted by Rank Top-Bottom Drug Delivery in Cancer - Technologies, Markets and Companies   Jain PharmaBiotech, Feb 2012, Pages: 639 in cancer drug delivery 2. Innovative treatments for cancer Introduction Selective estrogen receptor modulators Antiangiogenic strategies for cancer Development of antiangiogenic therapies Nitric Oxide - Therapeutics, Markets and Companies   Jain PharmaBiotech, Feb 2012, Pages: 276 modulators are described and compared along with developmental status. NO-related mechanisms of action in existing drugs are identified. Various pharmacological approaches are described along Preclinical Cancer Therapeutics 2007: Decoding Next Generation Drug Targets for Market Success   Spectra Intelligence, Nov 2006, Pages: 367 . Important themes covered in this chapter include rational drug design approaches, recombinant DNA technologies applied to drug discovery, and tumour-targeted approaches. Taken together, these therapeutic Cancer Drug Resistance   BioPharm Reports (VennBio Ltd.), Jan 2009, Pages: 235 includes proposed resistance mechanisms associated with CSCs, drug discovery strategies for the targeting of these cells, the current CSC-targeting drug development pipeline and the potential of these cells Cell Therapy - Technologies, Markets and Companies   Jain PharmaBiotech, Feb 2012, Pages: 1008 is replacing the old fashioned bone marrow transplants. Role of cells in drug discovery is also described. Cell therapy is bound to become a part of medical practice. Stem cells are discussed in detail in one RNAi - Technologies, Markets and Companies   Jain PharmaBiotech, Feb 2012, Pages: 485 RNAs for anticancer drug discovery siRNAs for inducing cancer immunity siRNAs for inhibition of angiogenesis siRNA targeting the R2 subunit of ribonucleotide reductase siRNA for cancer chemoprevention siHybrids vs Pipeline Insight: Small Molecule Targeted Cancer Therapies - New targets set to drive growth   Datamonitor, April 2010, Pages: 243 with greater efficacy Small molecules Small molecules targeting tyrosine kinases have been a significant development in oncology drug discovery Classification of pipeline products Angiogenesis inhibitor Cancer Therapies - Global Strategic Business Report   Global Industry Analysts, Inc., Oct 2011, Pages: 897 Inhibitors 32 Angiogenesis Inhibitors 32 List of Approved Angiogenesis Inhibitors 32 Proteasome Inhibitors 32 Multi-Targeted Drugs 32 Select Approved Multi-Targeted Drugs in Targeted Cancer Therapy 33 Triple Analysis: Decoding Big Pharma's R&D Strategy in Oncology and Special Focus on Leukemias and Lymphomas   Bioseeker, Sep 2007, Pages: 500 oncology areas; Breast- and Prostate cancer. And provide a framework but also a careful identification and evaluation of drug candidates, technologies and competitors. Decoding Big Pharma’s R&D Strategy Histone Deacetylase inhibitors   Lead Discovery, May 2005 is targeted at all involved in drug development extending from preclinical drug discovery personnel to business development managers and strategists. Summary of key issues & conclusions - The field of HDAC Drug Targets for Breast Cancer   Informa Healthcare, Jan 2006, Pages: 170 generally target key signaling molecules/pathways associated with cancer development. These include drugs that target growth factor receptors (e.g. the EGF or IGF receptor), angiogenesis, farnesylation Diabetic Foot Ulcer (DFU) Therapeutics - Pipeline Assessment and Market Forecasts to 2017   GlobalData, March 2011, Pages: 92 such as angiotensin analog, topoisomerases inhibitor, PKC modulator, PDGF modulator, adenosine A2a receptor agonist, cytokines modulater, protein synthesis inhibitor, Antithrombin III activator, cell wall or cell New Concepts in Cancer Therapeutics   Bioseeker, Dec 2005 -angiogenesis Box 7: New Target - EGF Like Domain Box 8: Kinesin Development Patents Box 9: Competitive Patents to those of Adherix Box 10: Important Targets in Cancer Drug Discovery Box 11: DS Modelling Targeting endogenous inhibitors of apoptosis: Opportunities for the treatment of cancer, stroke and MS   Lead Discovery, Jan 2003, Pages: 65 is now CEO and chief analyst at LeadDiscovery and coordinates the identification of candidate drug discovery projects with industrial potential. Background Apoptosis A general introduction to apoptosis XIVth International Symposium on Medicinal Chemistry. Pharmacochemistry Library Part No. 28   Elsevier Science and Technology, Sep 1997, Pages: 65 and fibrates. 40. Cardiovascular new drug discovery of the future: molecules, genes and machines. 41. The action of serpins and heparin as leads in drug discovery. 42. Inverse isostere strategies Results:  First -   Prev -   1 -   Next -   Last

		For enquiries please call us on:   +353-1-415-1241 (GMT Office Hours)   1-800-526-8630 (US/Canada Toll Free)   1-917-300-0470 (EST Office Hours)

All rights reserved. © Copyright 2012 Research and Markets3    Terms and conditions Privacy Policy Publishers Employment Opportunities Site Map Link to us Webmaster Affiliate Network